
Arrowhead Pharmaceuticals, Inc.
ARWRHealthcare|Biotechnology|US
$58.16
+0.70 (+1.22%)
Tangible Book / Share
$3.21
Cash / Share
$11.17
Financing Filings (last 12 months)
5
Shelf registrations / offering prospectuses — latest Jan 9, 2026 (424B5). Possible dilution.
Upcoming Data Readouts (14)
Dec 2026
Est. completion
P1Spinocerebellar Ataxia Type 2
Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2
NCT06672445n=39
Feb 2027
Est. completion
P1P2Obesity
A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus
NCT06937203n=150
Jun 2027
Est. completion
P1P2Alzheimer Disease
Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease
NCT07221344n=112
Jun 2027
Est. completion
NAOpioid Use Disorder
Adaptive Interventions for Emergency Department Patients With Opioid Use Disorder
NCT06827288n=500
Jul 2027
Est. completion
P1P2Hyperlipidemia; Mixed
Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia
NCT07223658n=78
Aug 2027
Est. completion
P3Homozygous Familial Hypercholesterolemia
A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)
NCT07037771n=70
Oct 2027
Est. completion
P1P2Obesity
A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus
NCT06700538n=190
Dec 2027
Est. completion
Mar 2028
Est. completion
Jul 2028
Est. completion
P1Age-related Macular Degeneration
A First-In-Human Study of ARO-033 in Adult Participants
NCT07662096n=84
Jul 2028
Est. completion
P3Hypertriglyceridemia
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
NCT06822790n=710
Jul 2028
Est. completion
P3Homozygous Familial Hypercholesterolemia
Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia
NCT07473843n=10
Dec 2028
Est. completion
Mar 2029
Est. completion
P3Severe Hypertriglyceridemia
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
NCT06880770n=288
Recent Press Releases
Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates
Nov 7, 2026 · Business Wire
Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity
Nov 4, 2026 · Business Wire
Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026
Nov 2, 2026 · Business Wire
Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides
Oct 27, 2026 · Business Wire
Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers
Oct 14, 2026 · Business Wire
Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia
Oct 7, 2026 · Business Wire
Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies
Sep 29, 2026 · Business Wire
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
Sep 15, 2026 · Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences
Sep 3, 2026 · Business Wire
SEC Filings (69)
Last two years from EDGAR. Insider Form 4s are on the Ownership tab.
| Filed | Form | What it is | Links |
|---|---|---|---|
| Nov 5, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Nov 4, 2026 | 8-K | Material event | DocumentIndex |
| Aug 14, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Aug 4, 2026 | 8-K | Material event | DocumentIndex |
| Aug 4, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Jul 31, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Jul 27, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Jun 16, 2026 | 8-K | Material event | DocumentIndex |
| May 7, 2026 | S-8 | Employee stock plan | DocumentIndex |
| May 7, 2026 | 10-Q | Quarterly report | DocumentIndex |
| May 7, 2026 | 8-K | Material event | DocumentIndex |
| May 6, 2026 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Apr 29, 2026 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Apr 28, 2026 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Apr 24, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Mar 26, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Mar 20, 2026 | 8-K | Material event | DocumentIndex |
| Feb 5, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Feb 5, 2026 | 8-K | Material event | DocumentIndex |
| Jan 27, 2026 | ARS | Annual report to holders | DocumentIndex |
| Jan 27, 2026 | DEFA14A | Proxy / shareholder vote | DocumentIndex |
| Jan 27, 2026 | DEF 14A | Proxy / shareholder vote | DocumentIndex |
| Jan 21, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Jan 12, 2026 | 8-K | Material event | DocumentIndex |
| Jan 9, 2026 | 8-K | Material event | DocumentIndex |
| Jan 9, 2026 | 424B5 | Offering prospectus | DocumentIndex |
| Jan 9, 2026 | 424B5 | Offering prospectus | DocumentIndex |
| Jan 8, 2026 | 305B2 | DocumentIndex | |
| Jan 8, 2026 | FWP | DocumentIndex | |
| Jan 8, 2026 | FWP | DocumentIndex | |
| Jan 7, 2026 | 424B5 | Offering prospectus | DocumentIndex |
| Jan 7, 2026 | 424B5 | Offering prospectus | DocumentIndex |
| Jan 6, 2026 | 8-K | Material event | DocumentIndex |
| Dec 11, 2025 | S-3ASR | Shelf registration | DocumentIndex |
| Nov 25, 2025 | 10-K | Annual report | DocumentIndex |
| Nov 25, 2025 | 8-K | Material event | DocumentIndex |
| Nov 18, 2025 | 8-K | Material event | DocumentIndex |
| Oct 10, 2025 | 10-K/A | Annual report | DocumentIndex |
| Sep 12, 2025 | 8-K | Material event | DocumentIndex |
| Sep 11, 2025 | 8-K | Material event | DocumentIndex |